<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02550873</url>
  </required_header>
  <id_info>
    <org_study_id>PRM-151-202</org_study_id>
    <nct_id>NCT02550873</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)</brief_title>
  <official_title>A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Promedior, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Promedior, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 2, randomized, double-blind, placebo controlled, pilot study designed
      to evaluate the efficacy and safety of PRM-151 administered through Week 24 to subjects with
      IPF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRM-151 is an anti-fibrotic immunomodulator being developed for treatment of fibrotic
      diseases.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 1, 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Actual">May 2, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Forced Vital Capacity (FVC) [% Predicted]</measure>
    <time_frame>0 to 28 weeks</time_frame>
    <description>Determine the effect size of PRM-151 relative to placebo in change from Baseline to Week 28 in mean FVC% predicted, pooling subjects on a stable dose of pirfenidone or nintedanib with subjects not on other treatment for IPF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 6-Minute Walk Distance (6MWD)</measure>
    <time_frame>0 to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Lung Volume on High-resolution Computed Tomography (HRCT)</measure>
    <time_frame>0 to 28 weeks</time_frame>
    <description>Mean change from baseline in total lung volume on HRCT using quantitative imaging software.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Volume of Interstitial Lung Abnormalities (ILA) on HRCT</measure>
    <time_frame>0 to 28 weeks</time_frame>
    <description>Mean change from baseline in volume of parenchymal features on HRCT representative of ILA, including ground glass density, reticular changes, and honeycombing, using quantitative imaging software</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in % of Total Lung Volume of ILA on HRCT</measure>
    <time_frame>0 to 28 weeks</time_frame>
    <description>Mean change from baseline in % of total lung volume of parenchymal features on HRCT representative of ILA, including ground glass density, reticular changes, and honeycombing, using quantitative imaging software</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Volume of Normal Lung on HRCT</measure>
    <time_frame>0 to 28 weeks</time_frame>
    <description>Mean change from baseline in volume of parenchymal features on HRCT representative of normal lung (non-ILA), including normal and mild low attenuation areas, using quantitative imaging software.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in % of Normal Lung on HRCT (%)</measure>
    <time_frame>0 to 28 weeks</time_frame>
    <description>Mean change from baseline in % of total lung volume of parenchymal features on HRCT representative of normal lung (non-ILA), including normal and mild low attenuation areas, using quantitative imaging software.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Between Mean Change From Baseline in FVC [% Predicted] and Mean Change From Baseline in ILA</measure>
    <time_frame>0 to 28 weeks</time_frame>
    <description>Correlation between mean change from Baseline in FVC [% predicted] and mean change from Baseline in volume of parenchymal features on HRCT representative of ILA, including ground glass density, reticular changes, and honeycombing by quantitative imaging software.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a Decline in FVC [% Predicted] of ≥ 5% and ≥ 10% From Baseline to Week 28.</measure>
    <time_frame>0 to 28 weeks</time_frame>
    <description>Pulmonary Function Tests for the Proportion (%) of subjects with a decline in FVC% predicted of ≥ 5% and ≥ 10% from Baseline to Week 28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a Decline in FVC of ≥ 100 mL and ≥ 200 mL From Baseline to Week 28.</measure>
    <time_frame>0 to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With an Increase in FVC [% Predicted] of ≥ 5% and ≥10% From Baseline to Week 28.</measure>
    <time_frame>0 to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With an Increase in FVC of ≥ 100 mL and ≥ 200 mL From Baseline to Week 28</measure>
    <time_frame>0 to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Stable Disease, Defined as a Change in FVC [% Predicted] of &lt; 5% From Baseline to Week 28.</measure>
    <time_frame>0 to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Stable Disease, Defined as a Change in FVC of &lt; 100 mL From Baseline to Week 28.</measure>
    <time_frame>0 to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in % Predicted Diffusion Capacity of Carbon Monoxide (DLCO).</measure>
    <time_frame>0 to 28 weeks</time_frame>
    <description>Pulmonary Function Tests to discern the mean change from Baseline to Week 28 in % predicted diffusion capacity of carbon monoxide (DLCO).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>0 to 28 weeks</time_frame>
    <description>Tolerability/safety was assessed over the 28-week study period by the number of reported TEAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Discontinuing Study Drug Due to AEs</measure>
    <time_frame>0 to 28 weeks</time_frame>
    <description>Tolerability/safety was assessed over the 28-week study period by the proportion of subjects who discontinued study drug due to AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Reporting Serious Adverse Events (SAEs)</measure>
    <time_frame>0 to 28 weeks</time_frame>
    <description>Tolerability/safety was assessed over the 28-week study period by incidence of SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Reporting Respiratory Decline AEs</measure>
    <time_frame>0 to 28 weeks</time_frame>
    <description>Tolerability/safety was assessed over the 28-week study period by the number of reported respiratory decline AEs, defined as follows:
Unscheduled visits to a healthcare professional for respiratory status deterioration.
Urgent care visits for respiratory status deterioration.
Hospitalization due to a worsening or exacerbation of respiratory symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Reporting Respiratory Decline SAEs [Safety and Tolerability]</measure>
    <time_frame>0 to 28 weeks</time_frame>
    <description>Tolerability/safety was assessed over the 28-week study period by the number of reported serious respiratory decline AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Infusion Related Reactions</measure>
    <time_frame>0 to 28 weeks</time_frame>
    <description>Infusion Related Reactions were defined as events of headache, fever, facial flushing, pruritus, myalgia, nausea, chest tightness, dyspnea, vomiting, erythema, abdominal discomfort, diaphoresis, shivers, hypertension, hypotension, lightheadedness, palpitations, urticaria and somnolence occurring between the start of a study treatment infusion and one hour after completion of the infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>0 to 28 weeks</time_frame>
    <description>Tolerability/safety was assessed over the 28-week study period by the incidence of all cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality Due to Respiratory Deterioration</measure>
    <time_frame>0 to 28 weeks</time_frame>
    <description>Tolerability/safety was assessed over the 28-week study period by the incidence of mortality due to respiratory deterioration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality Due to Disease Related Events</measure>
    <time_frame>0 to 28 weeks</time_frame>
    <description>Number of patients who died over the 28 week study period due to disease-related events (defined as cough, IPF exacerbation, IPF progression and respiratory decline AEs)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline in FVC Volume</measure>
    <time_frame>0 to 28 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">117</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>PRM-151 10mg / kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing Every 4 Weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dosing Every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PRM-151</intervention_name>
    <description>PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
    <arm_group_label>PRM-151 10mg / kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Is aged 40-80 years.

          2. Has IPF satisfying the American Thoracic Society/European Respiratory Society
             /Japanese Respiratory Society/Latin American Thoracic Association (ATS/ERS/JRS/ALAT)
             diagnostic criteria (Raghu, Collard et al. 2011). In the absence of a surgical lung
             biopsy, high-resolution computed tomography (HRCT) must be &quot;consistent with &quot;usual
             interstitial pneumonia&quot; (UIP) defined as meeting either criteria A, B, and C, or
             criteria A and C, or criteria B and C below:

               -  Definite honeycomb lung destruction with basal and peripheral predominance.

               -  Presence of reticular abnormality AND traction bronchiectasis consistent with
                  fibrosis, with basal and peripheral predominance.

               -  Atypical features are absent, specifically nodules and consolidation. Ground
                  glass opacity, if present, is less extensive than reticular opacity pattern.

          3. If on pirfenidone or nintedanib, subject must have been on a stable dose of
             pirfenidone or nintedanib for at least 3 months without increase in forced vital
             capacity (FVC)% predicted on two consecutive pulmonary function tests (PFTs),
             including screening PFTs. Subjects may not be on both pirfenidone and nintedanib.

          4. If not currently receiving pirfenidone or nintedanib, subject must have been off
             pirfenidone or nintedanib for ≥ 4 weeks before baseline.

          5. Has a FVC ≥ 50% and ≤ 90% of predicted.

          6. Has a DLCO ≥ 25% and ≤ 90% of predicted.

          7. Minimum distance on 6-Minute Walk Test (6MWT) of 150 meters.

          8. Has a forced expiratory volume in 1 second (FEV1)/FVC ratio &gt; 0.70.

          9. Women of child bearing potential (WCBP), defined as a sexually mature woman not
             surgically sterilized or not post-menopausal for at least 24 consecutive months if ≤
             55 years or 12 months if &gt; 55 years, must have a negative serum pregnancy test within
             four weeks prior to the first dose of study drug and must agree to use adequate
             methods of birth control throughout the study. Adequate methods of contraception are
             defined in the protocol.

         10. Has a life expectancy of at least 9 months

         11. According to the investigator's best judgment, can comply with the requirements of the
             protocol.

         12. Has provided written informed consent to participate in the study.

        Exclusion Criteria:

          1. Has emphysema ≥ 50% on HRCT or the extent of emphysema is greater than the extent of
             fibrosis according to reported results from the most recent HRCT.

          2. Has a history of cigarette smoking within the previous 3 months.

          3. Has received investigational therapy for IPF within 4 weeks before baseline.

          4. Is receiving systemic corticosteroids equivalent to prednisone &gt; 10 mg/day or
             equivalent within 2 weeks of baseline.

          5. Received azathioprine, cyclophosphamide, or cyclosporine A within 4 weeks of baseline.

          6. Has a history of a malignancy within the previous 5 years, with the exception of basal
             cell skin neoplasms. In addition, a malignant diagnosis or condition first occurring
             prior to 5 years must be considered cured, inactive, and not under current treatment.

          7. Has any concurrent condition other than IPF that, in the Investigator's opinion, is
             unstable and/or would impact the likelihood of survival for the study duration or the
             subject's ability to complete the study as designed, or may influence any of the
             safety or efficacy assessments included in the study.

          8. Has baseline resting oxygen saturation of &lt; 89% on room air or supplemental oxygen.

          9. Is unable to refrain from use of the following:

               -  Short acting bronchodilators on the day of and within 12 hours of pulmonary
                  function, DLCO, and 6 minute walk assessments.

               -  Long acting bronchodilators on the day of and within 24 hours of these
                  assessments.

         10. Has a known post bronchodilator (short acting beta agonist [SABA] - albuterol or
             salbutamol) increase in FEV1 of &gt;10% and in FVC of &gt;7.5%.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernt van den Blink, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Promedior, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Interstitial Lung Disease Program</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Medical and Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT - Southwestern Medical School</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75930</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomayer Hospital</name>
      <address>
        <city>Prague</city>
        <zip>14059</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Justus-Liebig University Giessen</name>
      <address>
        <city>Giessen</city>
        <zip>D-35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Ospedaliera Universitaria-Policlinico V. Emanuele di Catania</name>
      <address>
        <city>Catania</city>
        <zip>78-95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid Holland</state>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital University de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois (CHUV)</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Israel</country>
    <country>United Kingdom</country>
  </removed_countries>
  <results_reference>
    <citation>Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Santin-Janin H, Mulder GJ, Bartholmai B, Gupta R, Richeldi L. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial. JAMA. 2018 Jun 12;319(22):2299-2307. doi: 10.1001/jama.2018.6129.</citation>
    <PMID>29800034</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>August 27, 2015</study_first_submitted>
  <study_first_submitted_qc>September 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2015</study_first_posted>
  <results_first_submitted>November 20, 2018</results_first_submitted>
  <results_first_submitted_qc>November 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 14, 2018</results_first_posted>
  <last_update_submitted>May 30, 2019</last_update_submitted>
  <last_update_submitted_qc>May 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 3, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT02550873/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 8, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT02550873/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>One hundred fifty-one (151) patients were screened for the study. Of these, one hundred seventeen (117) were found to be eligible and were randomized. One randomized patient dropped out of the study prior to receiving any study drug.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>PRM-151 10 mg/kg</title>
          <description>Dosing Every 4 Weeks
PRM-151: PRM-151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
        </group>
        <group group_id="P3">
          <title>Open Label PRM-151 10 mg/kg</title>
          <description>Dosing Every 4 Weeks
PRM-151: PRM-151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized Double Blind</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Continue to Open Label Extension</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open Label Extension</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0">Open Label extension is ongoing</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="111"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study ongoing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="111"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All treated patients</population>
      <group_list>
        <group group_id="B1">
          <title>PRM-151 10 mg/kg</title>
          <description>Dosing Every 4 Weeks
PRM-151: PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="77"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="116"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Ethnicity/Race</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black/African</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86.1" spread="15.2"/>
                    <measurement group_id="B2" value="87.5" spread="13.4"/>
                    <measurement group_id="B3" value="86.5" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Years since IPF diagnosis, mean (SD)</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.74" spread="2.16"/>
                    <measurement group_id="B2" value="3.90" spread="2.62"/>
                    <measurement group_id="B3" value="3.79" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FVC</title>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2733" spread="630"/>
                    <measurement group_id="B2" value="2763" spread="654"/>
                    <measurement group_id="B3" value="2743" spread="635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FVC [% predicted]</title>
          <units>Percentage of predicted FVC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.7" spread="10.9"/>
                    <measurement group_id="B2" value="67.4" spread="11.4"/>
                    <measurement group_id="B3" value="67.6" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1/FVC</title>
          <units>Percentage of FEV1/FVC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.2" spread="5.1"/>
                    <measurement group_id="B2" value="81.6" spread="4.7"/>
                    <measurement group_id="B3" value="81.3" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin-corrected DLCO</title>
          <units>Percentage of predicted DLCO</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.1" spread="9.1"/>
                    <measurement group_id="B2" value="43.2" spread="10.5"/>
                    <measurement group_id="B3" value="41.2" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>6MWD</title>
          <units>meters</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="434.8" spread="92.5"/>
                    <measurement group_id="B2" value="457.7" spread="117.7"/>
                    <measurement group_id="B3" value="442.5" spread="101.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SpO2 at rest</title>
          <units>Percentage of SpO2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95.6" spread="2.1"/>
                    <measurement group_id="B2" value="95.5" spread="1.8"/>
                    <measurement group_id="B3" value="95.6" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IPF Therapy Status at Baseline</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Concurrent IPF Therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concurrent pirfenidone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concurrent nintedanib</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No concurrent IPF therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IPF therapy naiive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Comorbid Conditions</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>GERD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coronary Artery Disorders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Emphysema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Forced Vital Capacity (FVC) [% Predicted]</title>
        <description>Determine the effect size of PRM-151 relative to placebo in change from Baseline to Week 28 in mean FVC% predicted, pooling subjects on a stable dose of pirfenidone or nintedanib with subjects not on other treatment for IPF.</description>
        <time_frame>0 to 28 weeks</time_frame>
        <population>All treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 10 mg/kg</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM-151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Vital Capacity (FVC) [% Predicted]</title>
          <description>Determine the effect size of PRM-151 relative to placebo in change from Baseline to Week 28 in mean FVC% predicted, pooling subjects on a stable dose of pirfenidone or nintedanib with subjects not on other treatment for IPF.</description>
          <population>All treated patients</population>
          <units>Percentage of predicted FVC</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" lower_limit="-3.2" upper_limit="-1.8"/>
                    <measurement group_id="O2" value="-4.8" lower_limit="-5.7" upper_limit="-3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The sample size calculation was based on the following assumptions:
Normal distribution Homogeneity of variance the same in both arms, and for both types of patients Randomization ratio PRM-151:placebo = 2:1 Expected value for patients on pirfenidone or nintedanib = -1.5 Expected value for patients on no other treatment = -3 Expected value for patients on PRM-151 ≥ 0.75 Standard deviation = 5 75% of patients on a stable dose of pirfenidone or nintedanib α=0.10 two-sided Power = 80%</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0014</p_value>
            <p_value_desc>a priori threshold for statistical significance = 0.10</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Random intercept; dependent variable=raw values at each time point; explanatory variables=stratum, treatment, time and treatment by time interaction</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.72</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 6-Minute Walk Distance (6MWD)</title>
        <time_frame>0 to 28 weeks</time_frame>
        <population>All treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 10 mg/kg</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 6-Minute Walk Distance (6MWD)</title>
          <population>All treated patients</population>
          <units>meters</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-8.6" upper_limit="7.6"/>
                    <measurement group_id="O2" value="-31.8" lower_limit="-43.0" upper_limit="-20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>This study was not powered to test hypothesis beyond the primary endpoint.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Random intercept; dependent variable=raw values at each time point; explanatory variables=stratum, treatment, time and treatment by time interaction.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>31.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.42</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>17.4</ci_lower_limit>
            <ci_upper_limit>45.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Lung Volume on High-resolution Computed Tomography (HRCT)</title>
        <description>Mean change from baseline in total lung volume on HRCT using quantitative imaging software.</description>
        <time_frame>0 to 28 weeks</time_frame>
        <population>All patients from the ATS population who had HRCT data at both the Baseline and Week 28 time points.</population>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 10 mg/kg; No Background Therapy</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks in patients not receiving concurrent pirfenidone or nintedanib</description>
          </group>
          <group group_id="O2">
            <title>PRM-151 10 mg/kg; Pirfenidone or Nintedanib</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks in patients receiving concurrent pirfenidone or nintedanib</description>
          </group>
          <group group_id="O3">
            <title>Placebo; No Background Therapy</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks in patients not receiving concurrent pirfenidone or nintedanib</description>
          </group>
          <group group_id="O4">
            <title>Placebo; Pirfenidone or Nintedanib</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks in patients receiving concurrent pirfenidone or nintedanib</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Lung Volume on High-resolution Computed Tomography (HRCT)</title>
          <description>Mean change from baseline in total lung volume on HRCT using quantitative imaging software.</description>
          <population>All patients from the ATS population who had HRCT data at both the Baseline and Week 28 time points.</population>
          <units>milliliters</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-103.8" lower_limit="-234.1" upper_limit="26.6"/>
                    <measurement group_id="O2" value="-108.1" lower_limit="-184.2" upper_limit="-31.9"/>
                    <measurement group_id="O3" value="-197.3" lower_limit="-341.2" upper_limit="-53.3"/>
                    <measurement group_id="O4" value="-201.6" lower_limit="-305.3" upper_limit="-97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2032</p_value>
            <p_value_desc>This study was not powered to test hypothesis beyond the primary endpoint.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Random intercept and slope; dependent variable=raw values; explanatory variables=stratum, treatment, time and treatment by time interaction.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>93.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>72.98</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.7</ci_lower_limit>
            <ci_upper_limit>214.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Volume of Interstitial Lung Abnormalities (ILA) on HRCT</title>
        <description>Mean change from baseline in volume of parenchymal features on HRCT representative of ILA, including ground glass density, reticular changes, and honeycombing, using quantitative imaging software</description>
        <time_frame>0 to 28 weeks</time_frame>
        <population>All patients from the ATS population who had HRCT data at both the Baseline and Week 28 time points.</population>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 10 mg/kg; No Background Therapy</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks in patients not receiving concurrent pirfenidone or nintedanib</description>
          </group>
          <group group_id="O2">
            <title>PRM-151 10 mg/kg; Pirfenidone or Nintedanib</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks in patients receiving concurrent pirfenidone or nintedanib</description>
          </group>
          <group group_id="O3">
            <title>Placebo; No Background Therapy</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks in patients not receiving concurrent pirfenidone or nintedanib</description>
          </group>
          <group group_id="O4">
            <title>Placebo; Pirfenidone or Nintedanib</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks in patients receiving concurrent pirfenidone or nintedanib</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Volume of Interstitial Lung Abnormalities (ILA) on HRCT</title>
          <description>Mean change from baseline in volume of parenchymal features on HRCT representative of ILA, including ground glass density, reticular changes, and honeycombing, using quantitative imaging software</description>
          <population>All patients from the ATS population who had HRCT data at both the Baseline and Week 28 time points.</population>
          <units>milliliters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.7" spread="49.65"/>
                    <measurement group_id="O2" value="80.9" spread="29.21"/>
                    <measurement group_id="O3" value="17.8" spread="55.26"/>
                    <measurement group_id="O4" value="49.0" spread="39.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4927</p_value>
            <p_value_desc>This study was not powered to test hypotheses beyond the primary endpoint.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Random intercept; dependent variable=raw values at each time point; explanatory variables=stratum, treatment, time and treatment by time interaction</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>31.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>46.33</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.0</ci_lower_limit>
            <ci_upper_limit>108.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in % of Total Lung Volume of ILA on HRCT</title>
        <description>Mean change from baseline in % of total lung volume of parenchymal features on HRCT representative of ILA, including ground glass density, reticular changes, and honeycombing, using quantitative imaging software</description>
        <time_frame>0 to 28 weeks</time_frame>
        <population>All patients from the ATS population who had HRCT data at both the Baseline and Week 28 time points.</population>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 10 mg/kg, no Background Therapy</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM-151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>PRM-151 10 mg/kg IV; Pirfenidone or Nintedanib</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo, no Background Therapy</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo; Pirfenidone or Nintedanib</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in % of Total Lung Volume of ILA on HRCT</title>
          <description>Mean change from baseline in % of total lung volume of parenchymal features on HRCT representative of ILA, including ground glass density, reticular changes, and honeycombing, using quantitative imaging software</description>
          <population>All patients from the ATS population who had HRCT data at both the Baseline and Week 28 time points.</population>
          <units>percentage of total lung volume</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="-0.9" upper_limit="6.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.0" upper_limit="5.1"/>
                    <measurement group_id="O3" value="1.5" lower_limit="-2.4" upper_limit="5.4"/>
                    <measurement group_id="O4" value="1.9" lower_limit="-0.8" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5835</p_value>
            <p_value_desc>This study was not powered to test hypotheses beyond the primary endpoint.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Random intercept; dependent variable=raw values at each time point; explanatory variables=stratum, treatment, time and treatment by time interaction</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.96</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>4.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Volume of Normal Lung on HRCT</title>
        <description>Mean change from baseline in volume of parenchymal features on HRCT representative of normal lung (non-ILA), including normal and mild low attenuation areas, using quantitative imaging software.</description>
        <time_frame>0 to 28 weeks</time_frame>
        <population>All patients from the ATS population who had HRCT data at both the Baseline and Week 28 time points.</population>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 10 mg/kg; No Background Therapy</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks in patients not receiving concurrent pirfenidone or nintedanib</description>
          </group>
          <group group_id="O2">
            <title>PRM-151 10 mg/kg; Pirfenidone or Nintedanib</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks in patients receiving concurrent pirfenidone or nintedanib therapy</description>
          </group>
          <group group_id="O3">
            <title>Placebo; No Background Therapy</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks in patients not receiving concurrent pirfenidone or nintedanib</description>
          </group>
          <group group_id="O4">
            <title>Placebo; Pirfenidone or Nintedanib</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks in patients not receiving concurrent pirfenidone or nintedanib</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Volume of Normal Lung on HRCT</title>
          <description>Mean change from baseline in volume of parenchymal features on HRCT representative of normal lung (non-ILA), including normal and mild low attenuation areas, using quantitative imaging software.</description>
          <population>All patients from the ATS population who had HRCT data at both the Baseline and Week 28 time points.</population>
          <units>milliliters</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-165.2" lower_limit="-347.2" upper_limit="16.8"/>
                    <measurement group_id="O2" value="-201.1" lower_limit="-307.6" upper_limit="-94.5"/>
                    <measurement group_id="O3" value="-208.8" lower_limit="-410.1" upper_limit="-7.5"/>
                    <measurement group_id="O4" value="-244.7" lower_limit="-389.9" upper_limit="-99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6707</p_value>
            <p_value_desc>This study was not powered to test hypotheses beyond the primary endpoint.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Random intercept; dependent variable=raw values at each time point; explanatory variables=stratum, treatment, time and treatment by time interaction</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>43.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>102.28</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-126.3</ci_lower_limit>
            <ci_upper_limit>213.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in % of Normal Lung on HRCT (%)</title>
        <description>Mean change from baseline in % of total lung volume of parenchymal features on HRCT representative of normal lung (non-ILA), including normal and mild low attenuation areas, using quantitative imaging software.</description>
        <time_frame>0 to 28 weeks</time_frame>
        <population>All patients from the ATS population who had HRCT data at both the Baseline and Week 28 time points.</population>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 10 mg/kg, no Background Therapy</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM-151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>PRM-151 10 mg/kg IV; Pirfenidone or Nintedanib</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo, no Background Therapy</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo; Pirfenidone or Nintedanib</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in % of Normal Lung on HRCT (%)</title>
          <description>Mean change from baseline in % of total lung volume of parenchymal features on HRCT representative of normal lung (non-ILA), including normal and mild low attenuation areas, using quantitative imaging software.</description>
          <population>All patients from the ATS population who had HRCT data at both the Baseline and Week 28 time points.</population>
          <units>percentage of total lung volume</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" lower_limit="-6.0" upper_limit="0.8"/>
                    <measurement group_id="O2" value="-3.3" lower_limit="-5.3" upper_limit="-1.3"/>
                    <measurement group_id="O3" value="-1.4" lower_limit="-5.1" upper_limit="2.4"/>
                    <measurement group_id="O4" value="-2.1" lower_limit="-4.8" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.52</p_value>
            <p_value_desc>This study was not powered to test hypotheses beyond the primary endpoint.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Random intercept; dependent variable=raw values at each time point; explanatory variables=stratum, treatment, time and treatment by time interaction</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.91</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.4</ci_lower_limit>
            <ci_upper_limit>1.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between Mean Change From Baseline in FVC [% Predicted] and Mean Change From Baseline in ILA</title>
        <description>Correlation between mean change from Baseline in FVC [% predicted] and mean change from Baseline in volume of parenchymal features on HRCT representative of ILA, including ground glass density, reticular changes, and honeycombing by quantitative imaging software.</description>
        <time_frame>0 to 28 weeks</time_frame>
        <population>All patients from the ATS population who had FVC and HRCT data at both the Baseline and Week 28 time points.</population>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 10 mg/kg</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Mean Change From Baseline in FVC [% Predicted] and Mean Change From Baseline in ILA</title>
          <description>Correlation between mean change from Baseline in FVC [% predicted] and mean change from Baseline in volume of parenchymal features on HRCT representative of ILA, including ground glass density, reticular changes, and honeycombing by quantitative imaging software.</description>
          <population>All patients from the ATS population who had FVC and HRCT data at both the Baseline and Week 28 time points.</population>
          <units>Correlation coefficient</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5027" lower_limit="-0.6686" upper_limit="-0.2812"/>
                    <measurement group_id="O2" value="-0.4570" lower_limit="-0.6880" upper_limit="-0.1279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Correlation analysis</non_inferiority_desc>
            <p_value>0.0001</p_value>
            <p_value_desc>This study was not powered to test hypotheses beyond the primary endpoint.</p_value_desc>
            <method>Pearson's correlation</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This study was not powered to test hypotheses beyond the primary endpoint.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Correlation analysis</non_inferiority_desc>
            <p_value>0.0069</p_value>
            <method>Pearson's correlation</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a Decline in FVC [% Predicted] of ≥ 5% and ≥ 10% From Baseline to Week 28.</title>
        <description>Pulmonary Function Tests for the Proportion (%) of subjects with a decline in FVC% predicted of ≥ 5% and ≥ 10% from Baseline to Week 28.</description>
        <time_frame>0 to 28 weeks</time_frame>
        <population>All treated patients with data at baseline and 28 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 10 mg/kg, no Background Therapy</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>PRM-151 10 mg/kg; Pirfenidone or Nintedanib</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo, no Background Therapy</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo; Pirfenidone or Nintedanib</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Decline in FVC [% Predicted] of ≥ 5% and ≥ 10% From Baseline to Week 28.</title>
          <description>Pulmonary Function Tests for the Proportion (%) of subjects with a decline in FVC% predicted of ≥ 5% and ≥ 10% from Baseline to Week 28.</description>
          <population>All treated patients with data at baseline and 28 weeks</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decline in % Predicted FVC ≥ 5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decline in % Predicted FVC ≥10%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4179</p_value>
            <p_value_desc>P-Value for decline in % Predicted FVC ≥ 5%. This study was not powered to test hypotheses beyond the primary endpoint.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Random intercept; dependent variable=raw values at each time point; explanatory variables=stratum, treatment, time and treatment by time interaction</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2184</p_value>
            <p_value_desc>P-Value for decline in % predicted FVC ≥ 10%. This study was not powered to test hypotheses beyond the primary endpoint.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Random intercept; dependent variable=raw values at each time point; explanatory variables=stratum, treatment, time and treatment by time interaction</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a Decline in FVC of ≥ 100 mL and ≥ 200 mL From Baseline to Week 28.</title>
        <time_frame>0 to 28 weeks</time_frame>
        <population>All treated patients with data at baseline and Week 28</population>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 10 mg/kg, no Background Therapy</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>PRM-151 10 mg/kg IV; Pirfenidone or Nintedanib</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo, no Background Therapy</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo; Pirfenidone or Nintedanib</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With a Decline in FVC of ≥ 100 mL and ≥ 200 mL From Baseline to Week 28.</title>
          <population>All treated patients with data at baseline and Week 28</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Decrease in FVC ≥ 100 mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease in FVC ≥ 200 mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7773</p_value>
            <p_value_desc>P-Value for decline in FVC ≥ 100 mL. This study was not powered to test hypotheses beyond the primary endpoint.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Random intercept; dependent variable=raw values at each time point; explanatory variables=stratum, treatment, time and treatment by time interaction</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5976</p_value>
            <p_value_desc>P-Value for decline in FVC ≥ 200 mL. This study was not powered to test hypotheses beyond the primary endpoint.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Random intercept; dependent variable=raw values at each time point; explanatory variables=stratum, treatment, time and treatment by time interaction</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With an Increase in FVC [% Predicted] of ≥ 5% and ≥10% From Baseline to Week 28.</title>
        <time_frame>0 to 28 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 10 mg/kg, no Background Therapy</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>PRM-151 10 mg/kg; Pirfenidone or Nintedanib</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo, no Background Therapy</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo; Pirfenidone or Nintedanib</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With an Increase in FVC [% Predicted] of ≥ 5% and ≥10% From Baseline to Week 28.</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Increase in % Predicted FVC ≥5%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase in % Predicted FVC ≥10%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.29</p_value>
            <p_value_desc>P-Value for increase in % predicted FVC ≥ 5%. P-Value for an increase in % predicted FVC ≥ 10% not reported. This study was not powered to test hypotheses beyond the primary endpoint.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Random intercept; dependent variable=raw values at each time point; explanatory variables=stratum, treatment, time and treatment by time interaction</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With an Increase in FVC of ≥ 100 mL and ≥ 200 mL From Baseline to Week 28</title>
        <time_frame>0 to 28 weeks</time_frame>
        <population>All treated patients with FVC data at Baseline and Week 28</population>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 10 mg/kg, no Background Therapy</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>PRM-151 10 mg/kg; Pirfenidone or Nintedanib</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo, no Background Therapy</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo; Pirfenidone or Nintedanib</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With an Increase in FVC of ≥ 100 mL and ≥ 200 mL From Baseline to Week 28</title>
          <population>All treated patients with FVC data at Baseline and Week 28</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Increase in FVC ≥ 100 mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increase in FVC ≥ 200 mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0508</p_value>
            <p_value_desc>P-Value for increase in FVC ≥ 100 mL. P-Value for increase in FVC ≥ 200 mL not reported. This study was not powered to test hypotheses beyond the primary endpoint.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Random intercept; dependent variable=raw values at each time point; explanatory variables=stratum, treatment, time and treatment by time interaction</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Stable Disease, Defined as a Change in FVC [% Predicted] of &lt; 5% From Baseline to Week 28.</title>
        <time_frame>0 to 28 weeks</time_frame>
        <population>All treated subjects with data at baseline and week 28</population>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 10 mg/kg, no Background Therapy</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM-151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>PRM-151 10 mg/kg IV; Pirfenidone or Nintedanib</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo, no Background Therapy</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo; Pirfenidone or Nintedanib</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Stable Disease, Defined as a Change in FVC [% Predicted] of &lt; 5% From Baseline to Week 28.</title>
          <population>All treated subjects with data at baseline and week 28</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6308</p_value>
            <p_value_desc>This study was not powered to test hypotheses beyond the primary endpoint.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Random intercept; dependent variable=raw values at each time point; explanatory variables=stratum, treatment, time and treatment by time interaction</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Stable Disease, Defined as a Change in FVC of &lt; 100 mL From Baseline to Week 28.</title>
        <time_frame>0 to 28 weeks</time_frame>
        <population>All treated subjects with FVC data at Baseline and Week 28</population>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 10 mg/kg, no Background Therapy</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM-151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>PRM-151 10 mg/kg; Pirfenidone or Nintedanib</title>
            <description>Dosing Every 4 weeks
PRM-151: PRM-151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo, no Background Therapy</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo; Pirfenidone or Nintedanib</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Stable Disease, Defined as a Change in FVC of &lt; 100 mL From Baseline to Week 28.</title>
          <population>All treated subjects with FVC data at Baseline and Week 28</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1846</p_value>
            <p_value_desc>This study was not powered to test hypothesis beyond the primary endpoint.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Random intercept; dependent variable=raw values at each time point; explanatory variables=stratum, treatment, time and treatment by time interaction</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in % Predicted Diffusion Capacity of Carbon Monoxide (DLCO).</title>
        <description>Pulmonary Function Tests to discern the mean change from Baseline to Week 28 in % predicted diffusion capacity of carbon monoxide (DLCO).</description>
        <time_frame>0 to 28 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 10 mg/kg, no Background Therapy</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM-151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>PRM-151 10 mg/kg IV; Pirfenidone or Nintedanib</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo, no Background Therapy</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo; Pirfenidone or Nintedanib</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in % Predicted Diffusion Capacity of Carbon Monoxide (DLCO).</title>
          <description>Pulmonary Function Tests to discern the mean change from Baseline to Week 28 in % predicted diffusion capacity of carbon monoxide (DLCO).</description>
          <units>percentage of predicted DLCO</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" lower_limit="-5.1" upper_limit="-0.5"/>
                    <measurement group_id="O2" value="-3.0" lower_limit="-4.4" upper_limit="-1.6"/>
                    <measurement group_id="O3" value="-2.4" lower_limit="-5.0" upper_limit="0.3"/>
                    <measurement group_id="O4" value="-2.5" lower_limit="-4.4" upper_limit="-0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7424</p_value>
            <p_value_desc>This study was not powered to test hypothesis beyond the primary endpoint.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Random intercept; dependent variable=raw values at each time point; explanatory variables=stratum, treatment, time and treatment by time interaction.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.31</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.6</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Treatment-emergent Adverse Events (TEAEs)</title>
        <description>Tolerability/safety was assessed over the 28-week study period by the number of reported TEAEs</description>
        <time_frame>0 to 28 weeks</time_frame>
        <population>Safety population (All randomized patients who received at least one dose of study treatment)</population>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 10 mg/kg</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM-151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Treatment-emergent Adverse Events (TEAEs)</title>
          <description>Tolerability/safety was assessed over the 28-week study period by the number of reported TEAEs</description>
          <population>Safety population (All randomized patients who received at least one dose of study treatment)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Discontinuing Study Drug Due to AEs</title>
        <description>Tolerability/safety was assessed over the 28-week study period by the proportion of subjects who discontinued study drug due to AEs</description>
        <time_frame>0 to 28 weeks</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 10 mg/kg</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM-151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Discontinuing Study Drug Due to AEs</title>
          <description>Tolerability/safety was assessed over the 28-week study period by the proportion of subjects who discontinued study drug due to AEs</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Reporting Serious Adverse Events (SAEs)</title>
        <description>Tolerability/safety was assessed over the 28-week study period by incidence of SAEs</description>
        <time_frame>0 to 28 weeks</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 10 mg/kg</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM-151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Reporting Serious Adverse Events (SAEs)</title>
          <description>Tolerability/safety was assessed over the 28-week study period by incidence of SAEs</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Reporting Respiratory Decline AEs</title>
        <description>Tolerability/safety was assessed over the 28-week study period by the number of reported respiratory decline AEs, defined as follows:
Unscheduled visits to a healthcare professional for respiratory status deterioration.
Urgent care visits for respiratory status deterioration.
Hospitalization due to a worsening or exacerbation of respiratory symptoms.</description>
        <time_frame>0 to 28 weeks</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 10 mg/kg</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Reporting Respiratory Decline AEs</title>
          <description>Tolerability/safety was assessed over the 28-week study period by the number of reported respiratory decline AEs, defined as follows:
Unscheduled visits to a healthcare professional for respiratory status deterioration.
Urgent care visits for respiratory status deterioration.
Hospitalization due to a worsening or exacerbation of respiratory symptoms.</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Reporting Respiratory Decline SAEs [Safety and Tolerability]</title>
        <description>Tolerability/safety was assessed over the 28-week study period by the number of reported serious respiratory decline AEs</description>
        <time_frame>0 to 28 weeks</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 10 mg/kg</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM-151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Reporting Respiratory Decline SAEs [Safety and Tolerability]</title>
          <description>Tolerability/safety was assessed over the 28-week study period by the number of reported serious respiratory decline AEs</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Infusion Related Reactions</title>
        <description>Infusion Related Reactions were defined as events of headache, fever, facial flushing, pruritus, myalgia, nausea, chest tightness, dyspnea, vomiting, erythema, abdominal discomfort, diaphoresis, shivers, hypertension, hypotension, lightheadedness, palpitations, urticaria and somnolence occurring between the start of a study treatment infusion and one hour after completion of the infusion.</description>
        <time_frame>0 to 28 weeks</time_frame>
        <population>All treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 10 mg/kg</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM-151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Infusion Related Reactions</title>
          <description>Infusion Related Reactions were defined as events of headache, fever, facial flushing, pruritus, myalgia, nausea, chest tightness, dyspnea, vomiting, erythema, abdominal discomfort, diaphoresis, shivers, hypertension, hypotension, lightheadedness, palpitations, urticaria and somnolence occurring between the start of a study treatment infusion and one hour after completion of the infusion.</description>
          <population>All treated patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Infusion Related Reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertensive crisis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Cause Mortality</title>
        <description>Tolerability/safety was assessed over the 28-week study period by the incidence of all cause mortality</description>
        <time_frame>0 to 28 weeks</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 10 mg/kg</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM-151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>All Cause Mortality</title>
          <description>Tolerability/safety was assessed over the 28-week study period by the incidence of all cause mortality</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality Due to Respiratory Deterioration</title>
        <description>Tolerability/safety was assessed over the 28-week study period by the incidence of mortality due to respiratory deterioration</description>
        <time_frame>0 to 28 weeks</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 10 mg/kg</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM-151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality Due to Respiratory Deterioration</title>
          <description>Tolerability/safety was assessed over the 28-week study period by the incidence of mortality due to respiratory deterioration</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality Due to Disease Related Events</title>
        <description>Number of patients who died over the 28 week study period due to disease-related events (defined as cough, IPF exacerbation, IPF progression and respiratory decline AEs)</description>
        <time_frame>0 to 28 weeks</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 10 mg/kg</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM-151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality Due to Disease Related Events</title>
          <description>Number of patients who died over the 28 week study period due to disease-related events (defined as cough, IPF exacerbation, IPF progression and respiratory decline AEs)</description>
          <population>Safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in FVC Volume</title>
        <time_frame>0 to 28 weeks</time_frame>
        <population>All treated subjects</population>
        <group_list>
          <group group_id="O1">
            <title>PRM-151 10 mg/kg</title>
            <description>Dosing Every 4 Weeks
PRM-151: PRM-151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FVC Volume</title>
          <population>All treated subjects</population>
          <units>milliliters</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-127.7" lower_limit="-181.8" upper_limit="-73.5"/>
                    <measurement group_id="O2" value="-242.3" lower_limit="-317.2" upper_limit="-167.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0416</p_value>
            <p_value_desc>This study was not powered to test hypothesis beyond the primary endpoint.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Random intercept and slope; dependent variable=raw values; explanatory variables=stratum, treatment, time and treatment by time interaction.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>114.6</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>56.10</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>22.2</ci_lower_limit>
            <ci_upper_limit>207.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>28 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PRM-151 10 mg/kg</title>
          <description>Dosing Every 4 Weeks
PRM-151: PRM-151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Dosing Every 4 weeks
placebo: Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Embolic Cerebral Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Idiopathic Pulmonary Fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="77"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="77"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Influenza-like illness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="77"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="77"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="77"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Idiopathic pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="77"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="77"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="77"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Productive Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dyspnea exertional</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="77"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A Publications Committee comprised of Investigators participating in the study and representatives from Promedior was formed to oversee the publication of the study results, which reflected the experience of all participating study centers. Subsequently, individual Investigators may publish results from the study in compliance with their agreement with the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study not designed to test secondary outcome measures. Diagnosis of IPF allowed “possible usual interstitial pneumonia.” HRCTs read locally, so reads may be heterogeneous. HRCTs are susceptible to inspiratory effort artifacts.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Renu Gupta, MD, Chief Medical Officer</name_or_title>
      <organization>Promedior Inc.</organization>
      <phone>856-722-9824</phone>
      <email>rgupta@promedior.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

